A PIONEERING Clackmannanshire-based health tech company has reached a milestone after completing 200,000 treatments with its innovative device.

Alloa-based company Emblation, which has developed a non-ablative treatment for common and plantar warts, recently attracted an eight-figure investment deal with its Swift medical device.

The technology uses microwaves to treat common skin problems and more than half of the 200,000 treatments have taken place outside the UK as the burgeoning Wee County firm pursues global expansion.

Jonathan Williamson, chief commercial officer at Emblation, said: “When our founders developed this technology, they knew they had come up with something very special – now we are really starting to see the fruits of that innovation.

“It’s telling that we have reached this milestone despite the fact that Swift was only launched in 2016.

“We are still very much in start-up mode, so to have achieved these levels in a mature market with an entirely new treatment is something to be extremely proud of.

“It’s also remarkable that we have reached this significant landmark despite the many challenges thrown up by the pandemic.

“It really is a testament to the clinics who have invested in our technology and the dedication they bring to providing the best new treatments to their patients.”

The number of treatments is split across several markets including the UK, Australia, Canada and the US.

The firm has also just staked its first foothold in the European market thanks to a deal earlier this year with a respected Munich firm which distributes specialist medical devices across Germany and Austria.

Jonathan added: “While this is brilliant news for Emblation, we never lose sight of the fact that the most important people in this picture are the patients.

“Happily, the more treatments we complete, the clearer it is that Swift delivers outstanding results.”

The portable microwave technology enables medical experts to resolve persistent common and plantar warts, or verrucae, with a simple microwave treatment and has won widespread praise and recognition within both the medical and technology arena.

Jonathan said: “We know that once podiatrists, dermatologists and other clinicians start using Swift it rapidly becomes an invaluable and profitable part of their business, because it is quick, easy to use and highly effective.”

Emblation was founded by Gary Beale and Eamon McErlean, who met during post-graduate studies at University in Edinburgh.

The pair went on to launch Swift in 2016, as a radical new treatment in the podiatry sector.